Phase 2 N=30 Papillary Serous Carcinoma of the Endometrium
Endometrial Cancer
Primary: Overall Survival at 2 Years and 5 Years — 93; 85 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=62 Immunohistochemical Evaluation of Protein P16 Expression in Ovarian Germ Cell Tumors.
Ovarian Neoplasms · Germ Cell Tumors · Immunohistochemistry
Primary: P16 Evaluation in Ovarian Germ Cell Tumors — 7; 4; 0; 6 units on a scale — p=0.001
Phase 2 N=50 Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies
Fallopian Tube Cancer · Ovarian Sarcoma · Ovarian Stromal Cancer
Primary: Acute Toxicity Rate — 6 percentage of participants
Phase 1 N=23 Laparoscopic Narrow Band Imaging for Detection of Occult Cancer Metastases
Gastrointestinal and Gynecologic Malignancies
Primary: Rate of Detectable Peritoneal Metastases — 0; 2 percentage of lesions
Phase 1 N=33 Phase I Trial of Oral Metronomic Topotecan and Oral Pazopanib to Treat Recurrent/Persistent Gynecologic Tumors
Gynecologic Tumors
Primary: Dose Limiting Toxicity (DLT) — 8; 23; 2 participants
Phase 2 N=28 Trial of Chemotherapy in Ovarian, Fallopian Tube and Peritoneal Carcinoma
Primary Peritoneal Carcinoma · Ovarian Carcinoma · Fallopian Tube Carcinoma
Primary: Percentage of Patients That Achieve Maximal Surgical Debulking — 10 Participants
Phase 2 N=32 Neoadjuvant Therapy for Ovarian Cancer
Epithelial Ovarian Cancer · Primary Peritoneal Cancer · Fallopian Tube Cancer
Primary: Number of Protocol Defined Adverse Events in Patients Receiving Neoadjuvant Carboplatin, Paclitaxel, and Bevacizumab — 7 protocol defined adverse events
N/A N=221 Prospective Multicenter Study in Patients With a Tumor Benign Ovarian Presumed on the Use of Algorithms Such as Roma and RMI and Tumor Markers Such as CA125 and HE4
Ovarian Tumor · Ovarian Cancer
Primary: Tumor Marker CA125 — 189; 4 U/mL — p=<0.001
N/A N=70 Hysterectomy by Transabdominal Laparoscopy or NOTES
Uterine Diseases
Primary: Successful Removal of the Uterus Without Conversion to Another Technique — 35; 35 Participants — p=0.0221
N/A N=204 Lymph Node Mapping in Patients With Endometrial Cancer
Endometrial Cancer
Primary: Negative Predictive Value of Sentinel Lymph Node Prediction of Metastatic Disease — 98.8 percentage of patients
N/A N=100 Adipocytokines in Endometrial Cancer
Endometrial Cancer · Obesity
Primary: Correlation Between Circulating Levels of These Markers and Demographic Characteristics. — 39; 42; 11; 8 Participants — p=0.026
Phase 3 N=12,167 Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil) (V501-015)
Cervical Cancer · Genital Warts
Primary: Incidence of the Composite Endpoint of Human Papillomavirus (HPV) 16/18-related Cervical Intraepithelial Neoplasia (CIN) 2 or Worse in the Base Study — 0.0; 0.4…
N/A N=15 [18F] Flourothymidine (FLT) PET/CT Imaging for Gynecologic Cancers
Gynecologic Cancer
Primary: Patients With Changes in Bone Marrow Assessed Through Images — 0; 4 Participants
Phase 2 N=35 A Study of Nivolumab in Selected Uterine Cancer Patients
Uterine Cancer · Endometrial Carcinoma · Carcinosarcoma
Primary: Progression-Free Survival — 64.7 percentage of patients
Phase 2 N=12 Feasibility Study of Pazopanib in Combination With Chemotherapy in Gynaecological Tumors
Primary Peritoneal Carcinoma · Tumor · Epithelial Ovarian Cancer
Primary: Number of Participants Experiencing Serious Adverse Events and Non-serious Adverse Events
N/A N=430 Determining the Sensitivity of Sentinel Lymph Nodes Identified With Robotic Fluorescence Imaging
Endometrial Cancer · Cervical Cancer
Primary: Estimate the Sensitivity of the Sentinel Lymph Node — 418 Participants
Phase 1 N=24 Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary
Carcinosarcoma, Ovarian
Primary: Proportion of Patients With Completion of 4 Cycles of CT + GB — 0.7826 proportion of patients
Phase 3 N=28 Extraperitoneal Para-aortic Lymph Node Dissection (EPLND) for Cervix
Cervical Squamous Cell Carcinoma · Adenosquamous Carcinoma · Adenocarcinoma
Primary: Overall Survival Rate
N/A N=12 Integrated Dose Escalation for Advanced, Localized Gynecologic Cancer (The IDEAL - GYN Trial)
Cancer of the Cervix · Cervical Neoplasms
Primary: Maximum Tolerated Dose of Integrated Boost Radiation Therapy, Administered With IMRT Technique With Concurrent Chemotherapy (Cisplatin). — 70 Gray (Gy)
Phase 2 N=90 Evaluation of Metformin, Targeting Cancer Stem Cells for Prevention of Relapse in Gynecologic Patients
Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Primary: Recurrence-Free Survival — 58.1; 55.6 percentage of patients
Phase 2 N=18 CerviPrep for Applying Topical Gemcitabine to the Cervix in Treating Patients With Primary Endometrial, Cervical, or Ovarian Epithelial Cancer
Cervical Cancer · Endometrial Cancer · Ovarian Cancer
Primary: Number of Patients With Measurable Concentration of Gemcitabine in Uterine Vein (dFdC) — 5 Participants
Phase 1 N=13 Vaccine Therapy in Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers
Fallopian Tube Cancer · Ovarian Cancer · Peritoneal Cavity Cancer
Primary: Number of Patients With Treatment-emergent Adverse Events — 12; 6; 6; 12 Participants
N/A N=200 Detection of SLN in Patients With Endometrial Cancer Undergoing Robotic Assisted Staging: Comparison of ISB and ICG
Endometrial Cancer
Primary: Number of Pelvic Sentinel Lymph Nodes (SLN) in Endometrial Cancer Patients Detected by Either ICG and/or ISB Dyes. — 1.25; 2.03 nodes
Phase 2 N=23 Vaginal Cuff Brachytherapy Followed by Chemotherapy in Patients With Endometrioid Cancer
Endometrial Cancer · Papillary Serous · Clear Cell Endometrial Cancer
Primary: Number of Patients With Progression-free Survival at 2 Years — 19 Participants
Early Phase 1 N=103 Implementation of a Rapid Recovery Program in Gynecologic Oncology Surgery: A Pilot Study
Cervical Cancer · Uterine Endometrial Cancer · Ovarian Cancer
Primary: Hospital Stay — 3.0; 3.0 Days — p=0.36
Phase 2 N=21 Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers
Cervical Cancer · Endometrial Cancer · Ovarian Cancer
Primary: Toxicity Rates of Patients Treated With Concurrent Avastin and Daily Pelvic Radiation With no Other Concurrent Chemotherapy — 766 Events
N/A N=47 Ultrasonic Aspiration Versus CO2 Laser Ablation for the Treatment of Vulvar Intraepithelial Neoplasia
Vulvar Intraepithelial Neoplasia (VIN)
Primary: Number of Participants With Recurrence of Dysplasia — 5; 8 Participants
N/A N=40 An Analysis of Presentation and Outcome Following Treatment of Pancreatic Endocrine Neoplasms
Pancreatic Endocrine Neoplasms
Primary: Nonfunctioning and Malignant Pancreatic Endocrine Neoplasms — 28; 12; 22; 18 participants
Phase 2 N=93 Image-Guided Gynecologic Brachytherapy
Cervical Cancer · Uterine Cancer · Vaginal Cancer
Primary: Mean Doses Given — 93.9; 63.2; 58.63 Gy
Phase 2 N=24 Gleevec Study for Patients With Ovarian Cancer
Ovarian Cancer
Primary: Overall Response Rate (ORR) — 0; 0 participants